Filter
1264
Filtered Results: 1264
Text search:
European
Center
for
Disease
Prevention
and
Control
Featured
Recommendations
130
New Publications
214
Language
Document type
No document type
581
Studies & Reports
305
Guidelines
211
Manuals
80
Strategic & Response Plan
34
Fact sheets
23
Situation Updates
13
Training Material
8
Online Courses
3
Brochures
2
Resource Platforms
2
App
1
Videos
1
Countries / Regions
Global
54
Western and Central Europe
47
India
29
Ukraine
27
Eastern Europe
27
Russia
27
Latin America and the Carribbean
22
Africa
22
Sierra Leone
19
Liberia
18
Kenya
17
Ethiopia
16
Eastern Europe and Central Asia
13
Nepal
11
Germany
11
Zambia
11
Myanmar / Burma
11
Philippines
10
Brazil
10
Nigeria
9
Uganda
9
Rwanda
9
Guinea
8
Senegal
8
Syria
8
Indonesia
8
Middle East and North Africa
8
Asia
8
Albania
8
Burkina Faso
7
Mozambique
7
West and Central Africa
7
South–East Asia Region
7
Zimbabwe
6
South Sudan
6
Cambodia
6
South Africa
6
Georgia
6
Tanzania
5
Thailand
5
Yemen
5
East and Southern Africa
5
Congo, Democratic Republic of
4
Ghana
4
Bangladesh
4
Malawi
4
Angola
4
Moldova
4
USA
3
Pakistan
3
Jordan
3
Afghanistan
3
Argentina
3
Namibia
3
Eswatini/ Swaziland
3
North Macedonia
3
Colombia
3
Western Pacific Region
3
Armenia
3
Tajikistan
3
Vietnam
3
France
3
Belarus
3
Guinea-Bissau
2
Cameroon
2
Haiti
2
Somalia
2
Turkey
2
Benin
2
Central African Republic
2
Ecuador
2
Bolivia
2
Lesotho
2
Sri Lanka
2
Chile
2
Paraguay
2
Venezuela
2
Laos
2
Romania
2
Kazakhstan
2
Gabon
2
Jamaica
2
United Kingdom
2
Spain
2
Saudi Arabia
1
Iraq
1
Lebanon
1
Egypt
1
China
1
Papua New Guinea
1
Sudan
1
Peru
1
Hungary
1
Honduras
1
El Salvador
1
Greece
1
Madagascar
1
Other region
1
Bhutan
1
Poland
1
Italy
1
Qatar
1
Estonia
1
Lithuania
1
Iran
1
North America
1
Turkmenistan
1
Belgium
1
Portugal
1
Authors & Publishers
Publication Years
Category
Countries
305
Clinical Guidelines
117
Public Health
86
Key Resources
53
Women & Child Health
42
Pharmacy & Technologies
13
Capacity Building
11
Toolboxes
COVID-19
160
Mental Health
153
HIV
135
AMR
90
TB
84
Rapid Response
53
Planetary Health
48
NCDs
43
Ebola
36
Global Health Education
30
Caregiver
30
Refugee
23
Conflict
21
Pharmacy
21
Health Financing Toolbox
21
Disability
20
NTDs
19
Zika
13
Specific Hazards
8
Natural Hazards
6
Cholera
5
Polio
3
Social Ethics
2
Health Financing
1
This interim guidance is for LTCF managers and corresponding infection prevention and ... (IPC) focal persons in LTCF and updates the guidance published in March 2020. The objective of this document is to provide guidance on IPC in LTCFs in the context of COVID-19 to 1) prevent COVID-19-virus from entering the facility and spreading within the facility, and 2) to support safe conditions for visiting through the rigorous application of IPC procedures for the residents’ well-being. WHO will update these recommendations as new information becomes available.
Availabel in English, French, Russian and Spanish
Infectious disease outbreaks and epidemics are increasing in frequency, scale and impact. Health care facilities can amplify the transmission of em...
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations ... community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons. The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
The WHO document "Integrating the prevention and control of noncommunicable diseases in HIV/AIDS...
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171
coun...
The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a li...
Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline
recommended
This second edition of the Infection prevention and control in the context of coronavirus disease...
Water, sanitation and hygiene (WASH) are critical in the prevention and care for all of the 17 n...
Biology, Diagnosis and Treatment, Epidemiology and Prevention
7 June 2021
The Africa Regulatory Taskforce is a joint effort established by the Africa Centres for Disease Control ... Prevention (Africa CDC), the African Union Development Agency (AUDA-NEPAD) coordinated African Medicines Regulatory Harmonization (AMRH) Initiative, and the World Health Organisation’s (WHO) African Vaccine Regulatory Forum (AVAREF) to enable and provide support for an effective regulatory framework for COVID-19 Vaccines in Africa.
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), ... stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor for developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
This technical package represents a select group of strategies based on the best available evidence to help communities and states sharpen their focus on prevention activities with the greatest pote...
Formularies are lists of antibiotics that are suggested for certain healthcare settings. In developing a recommended formulary, countries should consider the needs of patients and facilities where t...
Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force
Key stakeholders must be involved in the planning, implementation, monitoring and evaluation of NCD plans and programmes. Within a ministry of health there will be different types of stakeholders, s...
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clin...
This manual presents a compelling case for action on carbapenem-resistant organisms (CROs) and describes the linkages between the prevention ... control of CROs and the Global Action Plan on Antimicrobial Resistance (AMR). It describes how the eight recommendations contained within the World Health Organization (WHO) guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities relate to general measures (that is, the core components of infection prevention and control [IPC] programmes) that need to be in place in all countries and health care facilities to prevent and control health care-associated infections (HAIs). The use of a stepwise approach is proposed to support implementation and improvement, based on the evidence and experience of what has worked in several health care settings worldwide. The focus is on adoptable and adaptable information.
